期刊文献+

端粒复合体与冠心病的研究进展 被引量:1

Research advances in telomere complex and coronary heart disease
下载PDF
导出
摘要 端粒复合体由端粒DNA、端粒相关蛋白、端粒酶共同构成,是维持染色体DNA稳定的重要结构。多种心血管危险因素和不良生活方式均可造成端粒缩短加快,而健康的生活方式及他汀类药物则可减缓端粒缩短。在细胞、动物等研究基础上,多项端粒复合体与冠心病相关的临床研究,阐明了端粒复合体功能失调在冠心病的发生、发展、预后中起到的重要作用。冠心病患者外周血白细胞端粒长度明显缩短,端粒长度短是心血管事件再发的一个独立的危险因素,具有预测心血管事件预后的价值。目前,针对端粒长度缩短与冠心病相关的机制、端粒相关蛋白与冠心病的相关性以及白细胞亚群的研究等方面尚有研究空间。 Telomere complex is composed of telomere DNA, telomere-binding proteins and telomerase,which is an important structure to maintain the stability of chromosome DNA. A variety of cardiovascular risk factors and unhealthy lifestyle can lead to accelerated telomere shortening,and healthy lifestyle and statins can slow down the telomere shortening. On the basis of cell and animal researches,a lot of clinical researchesontelomere complex associated with coronary heart disease have elaborated that the role that telomere complex dysfunction plays in the occurrence,development and prognosis of coronary heart disease. In patients with coronary heart disease,the telomere length in peripheral leukocyte is shortened. A short telomere length is an independent risk factor incardiovascular event recurrence,and has the value topredict the outcome of cardiovascular events. At present,there are fewstudies about the mechanism of telomere length shortening and its relation ofcoronary heart disease,the correlation between telomere-binding proteins and coronary heart disease,and also lack this kind studyin leukocyte subsets.
机构地区 中国医学科学院
出处 《中国心血管杂志》 2016年第1期69-72,共4页 Chinese Journal of Cardiovascular Medicine
关键词 冠状动脉疾病 端粒 端粒相关蛋白 端粒酶 Coronary artery disease Telomere Telomere-binding proteins Telomerase
  • 相关文献

参考文献42

  • 1Nilsson PM,Tufvesson H,Leosdottir M,et al.Telomeres and cardiovascular disease risk:an update 2013[J].Transl Res,2013,162(6):371-380.DOI:10.1016/j.trsl.2013.05.004.
  • 2Longhese MP,Anbalagan S,Martina M,et al.The role of shelterin in maintaining telomere integrity[J].Frontiers in Bioscience,2012,17(1):1715-1728.DOI:10.2741/4014.
  • 3Chen LY,Lingner J.CST for the grand finale of telomere replication[J].Nucleus,2013,4(4):277-282.DOI:10.4161/nucl.25701.
  • 4Martinez P,Thanasoula M,Carlos AR,et al.Mammalian Rap1controls telomere function and gene expression through binding to telomeric and extratelomeric sites[J].Nat Cell Biol,2010,12(8):768-780.DOI:10.1038/ncb2081.
  • 5Teo H,Ghosh S,Luesch H,et al.Telomere-independent Rap1is an IKK adaptor and regulates NF-κB-dependent gene expression[J].Nat Cell Biol,2010,12(8):758-767.DOI:10.1038/ncb2080.
  • 6Narducci ML,Grasselli A,Biasucci LM,et al.High telomerase activity in neutrophils from unstable coronary plaques[J].J Am Coll Cardiol,2007,50(25):2369-2374.DOI:10.1016/j.jacc.2007.08.048.
  • 7Martínez P,Blasco MA.Telomeric and extra-telomeric roles for telomerase and the telomere-binding proteins[J].Nat Rev Cancer,2011,11(3):161-176.DOI:10.1038/nrc3025.
  • 8Ye J,Renault VM,Jamet K,et al.Transcriptional outcome of telomere signalling[J].Nat Rev Genet,2014,15(7):491-503.DOI:10.1038/nrg3743.
  • 9Aviv A,Hunt SC,Lin J,et al.Impartial comparative analysis of measurement of leukocyte telomere length/DNA content by Southern blots and q PCR[J].Nucleic Acids Res,2011,39(20):e134.DOI:10.1093/nar/gkr634.
  • 10Farzaneh-Far R,Lin J,Epel E,et al.Telomere length trajectory and its determinants in persons with coronary artery disease:longitudinal findings from the heart and soul study[J].PLo S One,2010,5(1):e8612.DOI:10.1371/journal.pone.0008612.

二级参考文献13

  • 1Counter C M, Meyerson M, Eaton E N, et al. Telomerase activity is restored in human cells by ectopic expression of hTERT (hEST2), the catalytic subunit of telomerase[J].Oncogene, 1998, 16(9): 1217-1222.
  • 2Walter D H, Rittig K, Bahlmann F H, et al. Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells[J]. Circulation, 2002, 105(25) : 3017 -3024.
  • 3Grisar J, Steiner C W, Bonelli M, et al. Systemic Lupus erythematosus patients exhibit functional deficiencies of endothelial progenitor cells [ J ]. Rheumatology ( Oxford), 2008, 47 ( 10) : 1476 - 1483.
  • 4Maellaro E, Pacenti L, Del-Bello B, et al. Different effects of interferon-alpha on melanoma cell lines: a study on telomerase reverse transcriptase, telomerase activity and apoptosis[J]. Br J Dermatol, 2003, 148(6) : 1115 -1124.
  • 5Dzau V J, Gnecehi M, Pachori A S, el al. Therapeutic potential of endothelial progenitor cells in cardiovascular diseases[J].Hypertension, 2005, 46(1): 7-18.
  • 6Umemura T, Soga J, Hidaka T, et al. Aging and hypertension are independent risk factors for reduced number of circulating endothelial progenitor cells[J]. Am J Hypertens, 2008, 21 ( 11 ) : 1203 - 1209.
  • 7Wang H Y, Gao P J, Ji K D, et al. Circulating endothelial progenitor cells, C-reactive protein anti severity of coronary stennsis in Chinese patients with coronary artery disease[J].Hypertens Res, 2007, 30 (2) : 133 - 141.
  • 8Kushner E J, Van-Guilder G P, Maceneaney O J, et al. Aging and endothelial progenitor cell telomere length in healthy men[J].Clin Chem Lab Med, 2009, 47 ( 1 ) : 47 - 50.
  • 9Satoh M, Ishikawa Y, Takahashi Y, et al. Assoeiation between oxidative DNA damage and telomere shortening in circulating endothelial progenitor cells obtained from metabolic syndrome patients with coronary artery disease[ J ]. Atherosclerosis, 2008, 198 (2) : 347 - 353.
  • 10Iwaguro H, Asahara T. Endothelial progenitor cell culture and gene transfer[ J]. Methods Mol Med, 2005, 112 : 239 -247.

共引文献7

同被引文献1

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部